Berenberg initiated coverage on POINT Biopharma with a new price target
$PNT
Biotechnology: Pharmaceutical Preparations
Health Care
Berenberg initiated coverage of POINT Biopharma with a rating of Buy and set a new price target of $20.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/20/2023 | $12.00 → $14.00 | Buy | Jefferies |
| 12/14/2022 | $10.00 | Outperform | Raymond James |
| 11/30/2022 | $14.00 | Outperform | SVB Leerink |
| 10/11/2022 | $20.00 | Outperform | Oppenheimer |
| 9/16/2022 | $22.00 | Buy | Truist |
| 9/14/2022 | $20.00 | Buy | Berenberg |
| 8/16/2022 | $20.00 | Buy | Guggenheim |
| 7/6/2022 | Outperform | William Blair |
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ:FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. In September, Oppenheimer initiated coverage on Fusion Pharmaceuticals, citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies. Most recently, Bristol Myers Squibb & Co (NYSE:BMY) has agreed to acquire RayzeBio Inc (NASDAQ:RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. On Wednesda
Brookline Capital analyst Kemp Dolliver downgrades POINT Biopharma Global (NASDAQ:PNT) from Buy to Hold and lowers the price target from $27 to $12.5.
Monday, Lantheus Holdings Inc (NASDAQ:LNTH) and POINT Biopharma Global Inc (NASDAQ:PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic castration-resistant prostate cancer after progression on an androgen receptor pathway inhibitor (ARPI). William Bliar writes that sharing the same survival trend as Novartis AG's (NYSE:NVS) Pluvicto effectively removes a potential bull thesis in which PNT2002 could potentially be on the market before Pluvicto in the disease setting. The analyst also notes that since Pluvicto demonstrated a numerically lower frequency of high-grade adverse events versus alternate novel hormone therapy in PSMAfore, the safety profile i
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c
INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ:PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, and Athebio AG ("Athebio"), an innovation leader in the discovery and design of designed ankyrin repeat proteins (DARPins), today announced a collaboration and license agreement to develop and commercialize DARPin-targeted radioligands ("Radio-DARPins"). DARPins are an attractive ligand class for cell-surface targets that could enable access to cell "surfaceome" targets beyond catalytic and ligand binding sites typically ac
Jefferies resumed coverage of POINT Biopharma with a rating of Buy and set a new price target of $14.00 from $12.00 previously
Raymond James initiated coverage of POINT Biopharma with a rating of Outperform and set a new price target of $10.00
SVB Leerink initiated coverage of POINT Biopharma with a rating of Outperform and set a new price target of $14.00
15-12G - POINT Biopharma Global Inc. (0001811764) (Filer)
EFFECT - POINT Biopharma Global Inc. (0001811764) (Filer)
EFFECT - POINT Biopharma Global Inc. (0001811764) (Filer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
4 - POINT Biopharma Global Inc. (0001811764) (Issuer)
INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ:PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ:PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition of POINT," said Jacob Van Naarden, executive vice president and president, Loxo@Lilly. "We welcome POINT colleagues to Lilly and look forward to working together to build on their work as we
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the appointment of Dr. Yael Margolin as an independent member of the Company's Board of Directors. Dr. Yael Margolin has more than 35 years of experience as senior manager, c
SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13D/A - POINT Biopharma Global Inc. (0001811764) (Subject)
SC 13D - POINT Biopharma Global Inc. (0001811764) (Subject)